Analyzing Williston (OTCMKTS:WHCA) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Williston (OTCMKTS:WHCA) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Valuation and Earnings

This table compares Williston and Swedish Orphan Biovitrum”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Williston	N/A	N/A	N/A	N/A	N/A
Swedish Orphan Biovitrum	$2.46 billion	5.04	$367.52 million	($0.07)	-498.29

Swedish Orphan Biovitrum has higher revenue and earnings than Williston.

Analyst Ratings

This is a summary of current ratings and recommmendations for Williston and Swedish Orphan Biovitrum, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Williston	0	0	0	0	0.00
Swedish Orphan Biovitrum	0	0	1	1	3.50

Given Williston’s higher probable upside, equities research analysts clearly believe Williston is more favorable than Swedish Orphan Biovitrum.

Profitability

This table compares Williston and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Williston	N/A	N/A	N/A
Swedish Orphan Biovitrum	-0.97%	13.61%	7.53%

Summary

Swedish Orphan Biovitrum beats Williston on 6 of the 8 factors compared between the two stocks.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.